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ABSTRACT In the course of determining the primary 
structure of rabbit skeletal muscle myosin light chain kinase 
(MLCK; ATP:protein phosphotransferase, EC 2.7.1.37) a 
peptide fragment was obtained that appears to represent the 
calmodulin-binding domain of this enzyme. Low concentra-
tions of the peptide inhibited calmodulin activation of MLCK 
(K, "" 1 nM). The peptide was not associated with a catalytical-
ly active, calmodulin-independent form of MLCK that was ob-
tained by limited proteolysis. The peptide is 27 residues in 
length and represents the carboxyl terminus of MLCK. The 
sequence of the peptide shows no significant homology with 
any known protein sequence. The peptide contains one trypto-
phanyl residue and a high percentage of basic and hydropho-
bic residues, but no acidic or prolyl residues. Much of the se-
quence has a high probability of forming a helix. A chemically 
synthesized peptide has been prepared to study the interac-
tions of the peptide and calmodulin in more detail. The intrin-
sic tryptophan fluorescence of the synthetic peptide shows a 
significant enhancement (-45 %) in the presence of Ca2+ and 
calmodulin; fluorescence enhancement is maximal at a pep-
tide:calmodulin stoichiometry of 1:1. Calmodulin-Sepharose 
affmity chromatography in the presence of 2 M urea indicates 
that the interaction of peptide and calmodulin is Ca2+ -depen-
dent. The results of these studies indicate that the catalytic and 
calmodulin-binding domains of MLCK represent distinct and 
separable regions of the protein. In addition, the results pro-
vide a basis for future studies of the molecular and evolution-
ary details of calmodulin-dependent enzyme regulation. 
Calmodulin is a Ca2+ -binding protein that is ubiquitously dis-
tributed and highly conserved throughout eukaryotic evolu-
tion. Although it is known to regulate many Ca2+ -dependent 
enzymes (recently reviewed in ref. 1), little is known about 
the interactions of calmodulin with these proteins at the mo-
lecular level. Myosin light chain kinase (MLCK; ATP:pro-
tein phosphotransferase, EC 2.7.1.37) is one of the better 
characterized calmodulin-regulated enzymes (reviewed in 
refs. 2 and 3) and is found in both muscle and nonmuscle 
tissues. The enzyme occurs in tissue-specific forms, which 
vary widely in molecular weight, antigenic determinants, 
and enzymatic properties (3, 4). It catalyzes the phosphoryl-
ation of a specific class of myosin light chain subunit, termed 
the P-light chain (5). In smooth muscle this phosphorylation 
is required for initiation of contraction (reviewed in refs. 2 
and 6), whereas in skeletal muscle the phosphorylation ap-
pears to modulate the degree of tension produced during iso-
metric contraction (3, 7). 
A determination of the amino acid sequence of rabbit skel-
etal muscle MLCK was undertaken by these severallabora-
tories as part of a long-range study of protein kinase and cal-
The publication costs ofthis article were defrayed in part by page charge 
payment. This article must therefore be hereby marked "advertisement" 
in accordance with 18 U.S.C. §l734 solely to indicate this fact. 
3187 
modulin-dependent enzyme structure. One of the goals in 
this endeavor was to identify the calmodulin-binding domain 
of this enzyme. The sequence and preliminary characteriza-
tion of a peptide derived from MLCK that displays the prop-
erties expected of a calmodulin-binding domain are de-
scribed in this report. This information should prove useful 
in understanding the evolutionary relationships of calmodu-
lin-dependent enzymes as well as the molecular mechanisms 
of calmodulin action. 
METHODS 
MLCK was purified from fresh rabbit skeletal muscle by a 
procedure similar to that described by Nagamoto and Vagi 
(8), details of which will be publis~ed elsewhere. The en-
zyme was subjected to limited proteolysis in order to gener-
ate lower molecular weight forms that retained catalytic ac-
tivity (unpublished data). With trypsin, a mixture of two 
forms with MrS of approximately 60,000 and 40,000 by Na-
DodS04/PAGE was generated. The mixture, which con-
tained nearly equal amounts ofthe two forms, was complete-
ly calmodulin-dependent and was termed T60/40. Evidence 
was obtained that the Mr 60,000 form was an intermediate 
form that could be further degraded to the Mr 40,000 form. A 
calmodulin-independent form of MLCK was generated by 
limited proteolysis with chymotrypsin. This form had a Mr of 
35,000 by NaDodS04/PAGE and showed identical catalytic 
activity in the presence of either 2 mM EGT A or 0.2 mM 
Ca2+ and 5 p.M calmodulin. This calmodulin-independent 
form of MLCK was denoted C35. Details of the preparation 
and properties of these proteolyzed forms of MLCK will be 
described elsewhere. CNBr digestions of intact MLCK, 
T60/40, and C35 were performed following reduction and S-
carboxymethylation as described by Takio et al. (9). After 
lyophilization, the CNBr digests were either dissolved in wa-
ter to assay for MLCK inhibition or fractionated by a combi-
nation of size exclusion and reversed-phase high-pressure 
liquid chromatography (HPLC). Details of peptide isolation 
and characterization will be presented elsewhere. 
Calmodulin was prepared from bovine testis by using 
batchwise DEAE-cellulose (DE-52, Whatman) chromatogra-
phy, phenyl-Sepharose (Sigma) chromatography (10), and 
gel filtration chromatography (Bio-Gel A-0.5m, Bio-Rad). 
Mixed myosin light chains from rabbit skeletal muscle were 
prepared as described (11). Standard solid-phase methods 
(12) were used for synthesizing the calmodulin-binding pep-
tide. The composition and sequence of the peptide were veri-
fied by amino acid analysis, Edman degradations, and pro-
ton NMR spectroscopy. [y-32p]ATP was obtained from New 
England Nuclear. 
Calmodulin-binding activity of peptides and CNBr digests 
Abbreviations: MLCK. myosin light chain kinase; Mops, 4-morpho-
linepropanesulfonic acid. 
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was determined by assaying for their ability to inhibit cal-
modulin-dependent MLCK activity. MLCK activity was de-
termined as described (11). All reaction mixtures (50 p.l final 
volume) contained 200 #£M CaCh, 10 mM magnesium ace-
tate, 2 mM [y-32p]ATP (=200 cpm/pmol), 15 mM 2-mercap-
toethanol, 50 mM 4-morpholinepropanesulfonic acid (Mops) 
at pH 7.0. Concentrations of proteins and peptides are indi-
cated in the figure legends. The following catalytic rates 
were determined for use in calculating apparent Kj values: 
Vo, the catalytic rate in the absence of any inhibitor or exoge-
nously added calmodulin (sufficient endogenous calmodulin 
was present in the myosin light chain preparation to give val-
ues for vo/V max of 0.3-0.4); Vj, the catalytic rate in the pres-
ence of inhibitor and no exogenously added calmodulin; 
V max, the catalytic rate in the presence of 1 #£M exogenously 
added calmodulin. The apparent Kj value for a given inhibi-
tor was calculated by using the equation: 
[I] 
Kj = -------------{Vmax/vJ - 1 
(V max/vol - 1 
KCaM 
Vmax/Vj - l' 
- 1 
where [I] is the inhibitor concentration and KCaM is the con-
centration of calmodulin required for half-maximal activa-
tion (a value of 1.0 nM was used for KCaM in all calculations). 
The equation assumes simple competition for Caa+ 'calmodu-
lin between the inhibitor and MLCK. The Kj values stated in 
the text were calculated only for 0.1 < Vj/vo < 0.9. 
RESULTS 
In the course of the primary structure determination of rab-
bit skeletal muscle MLCK, it was of interest to know wheth-
er any fragments of the enzyme retained the ability to bind 
calmodulin. Digestion of the enzyme with CNBr yielded a 
number of moderate-size fragments that might be expected 
to retain some affinity for calmodulin. To assay various di-
gests and isolated fragments for calmodulin-binding activity, 
the ability of a sample to inhibit MLCK activity was mea-
sured in a reaction mixture in which calmodulin was limiting 
(see Methods). As shown in Fig. 1, an unfractionated CNBr 
digest of MLCK was inhibitory at low concentrations. The 
apparent Kj value was calculated to be 4.5 nM. This value is 
in good agreement with the activation (0.3 nM) and binding 
(3 nM) constants reported for MLCK interaction with cal-
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FIG. 1. Inhibition of calmodulin-dependent MLCK activity by 
various unfractionated CNBr digests of MLCK. CNBr digests of 
intact MLCK (e), T60/40 (0), and C35 (0) were prepared and as-
sayed for their ability to inhibit calmodulin-sensitive MLCK activi-
ty. Indicated concentrations were determined by amino acid analy-
sis assuming MrS of 81,000, 40,000, and 35,000 for intact MLCK, 
T60/40, and C35, respectively. The concentrations of enzyme and 
myosin light chains were 0.78 nM and 47 ~, respectively. Catalytic 
rates are expressed relative to Yo. 
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modulin (13, 14). To establish whether loss of calmodulin 
sensitivity was related to the loss of a calmodulin-binding 
fragment, CNBr digests of various proteolyzed forms of 
MLCK were assayed for inhibitory activity (Fig. 1; see 
Methods for description of nomenclature). The unfraction-
ated CNBr digest ofT60/4O (a form which retains calmodu-
lin dependence) was inhibitory at low concentrations (Kj = 
1.3 nM). The CNBr digest of C35 (a form lacking calmodulin 
dependence), however, showed a marked reduction (by a 
factor of 38) in the ability to inhibit (Kj = 170 nM). These 
data are consistent with there being a high-affinity calmodu-
lin-binding fragment in CNBr digests of calmodulin-depen-
dent forms of MLCK (intact MLCK and T60/4O), which is of 
much lower affinity and/or quantity in CNBr digests of a 
calmodulin-independent form of the enzyme (C35). 
Assays of several isolated CNBr fragments (Fig. 2) indi-
cated that one peptide, termed M13, exhibited nearly all of 
the inhibitory capacity (Kj = 9 nM) of the unfractionated di-
gest. Two other fragments, Ml1-12 and M12, showed no in-
hibitory ability. Peptide maps of CNBr digests of MLCK and 
C35 indicated that M13 was degraded to a much shorter form 
in C35, whereas fragment M12 was found in digests of both 
C35 and MLCK (unpublished observations). A peptide cor-
responding to the sequence of M13 (see Fig. 3 for sequence) 
but lacking a carboxyl terminus homoserine was synthesized 
and assayed for its ability to inhibit calmodulin-dependent 
MLCK activity. This synthetic peptide showed the highest 
potency (Kj = 0.9 nM) of any material tested (data not 
shown). The lower inhibitory potency of M13 as isolated 
from the CNBr digest was probably due to side reactions of 
sensitive side chains (e.g., tryptophan oxidation, asparagine 
deamidation), which tend to occur under the relatively harsh 
conditions of CNBr digestion and the subsequent purifica-
tion procedures. When high concentrations of calmodulin (1 
#£M) were included in the assay, the same MLCK activity 
was observed in the presence or absence of synthetic M13 
(40 nM), indicating that the mechanism of peptide inhibition 
was through calmodulin and not by a direct effect on MLCK 
(data not shown). 
The sequence of the inhibitory peptide contains a trypto-
phanyl residue; therefore, it was of interest to investigate the 
interaction of the synthetic inhibitory peptide with calmodu-
lin by using the intrinsic fluorescence ofthe peptide (Fig. 4). 
Fluorescence enhancement was maximal (=45%) at a molar 
ratio of 1 mol of peptide per mol of calmodulin, consistent 
with the stoichiometry of interaction between intact MLCK 
and calmodulin (8, 11, 14, 19-22). Similar increases in tryp-
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FIG. 2. Inhibition of calmodulin-dependent MLCK activity by 
isolated CNBr fragments of MLCK. CNBr fragments Mll-12 (t.), 
M12 (0), and M13 (0) were quantitated by amino acid analysis. An 
unfractionated CNBr digest ofMLCK (e) was prepared and quanti-
tated as described in the legend to Fig. 1. The concentrations of 
enzyme and myosin light chains were 1.6 nM and 94 ~, respective-
ly. Catalytic rates are expressed relative to Yo· 
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FIG. 3. Structural profile of the calmodulin-binding peptide de-
rived from MLCK. (Upper) Chou-Fasman (15) probabilities for a 
helix ( ........ ). fJ strand (l>--l». and fJ turn (A-A). averaged over four 
residues using the program of Corrigan and Huang (16) and data 
from Argos et al. (17). (Lower) Hydropathy profile of the sequence 
using the values reported in Kyte and Doolittle (18). The hydropathy 
values were not averaged. The peptide sequence is shown between 
the panels using the one-letter code described in the legend to Table 
1. The basic residues. lysine (K) and arginine (R). are indicated in 
boldface to emphasize their positions in the sequence. The carboxyl-
terminal methionine (M) is not present in the synthetic peptide. 
tophan fluorescence intensity were reported for MLCK in-
teraction with calmodulin (21). Because of the relatively high 
concentrations of peptide and calmodulin required for fluo-
rometric measurements (1.3 JLM). accurate determinations 
of binding affinities cannot be obtained; however. the fluo-
rescence data indicate that the interaction of peptide and cal-
modulin is of high affinity (Kd < 10 nM). consistent with the 
affinity determined by the inhibition assay. 
To determine whether the interaction of the peptide with 
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FIG. 4. Stoichiometry of calmodulin-peptide interaction as de-
termined by peptide intrinsic tryptophan fluorescence. Synthetic 
peptide (1.3 ~M) corresponding to M13 was titrated with calmodulin 
(CaM) in 0.2 mM CaC12/20 mM Mops. pH 7.0/100 mM NaCI. Tryp-
tophan emission was monitored at 355 nm with an excitation wave-
length of 295 nm by using a Perkin-Elmer MPF-44A recording Spec-
trofluorometer. Concentrations of peptide and calmodulin were de-
termined by UV absorption with the molar extinction coefficients 
£280 = 5555 and £276 = 3300. respectively. The intersecting lines 
were drawn to best fit the points between O:s [CaM]/[peptide] :s 1.0 
and 1.0 :s [CaM]/[peptide] :s 5.3. respectively. Data are expressed 
as the ratio of observed fluorescence (F) to peptide fluorescence in 
the absence of calmodulin (Fo). 
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calmodulin is Ca2+ -dependent. chromatography of the pep-
tide on calmodulin-Sepharose was employed. Calmodulin 
was coupled to CNBr-activated Sepharose 4B (Pharmacia) 
to the extent of ... 5 mg of calmodulin per ml of packed Seph-
arose (23). The column (0.6 x 8 cm) was equilibrated in 2 M 
urea/0.2 M ammonium acetate, pH 6.8/0.2 mM CaCh, and 
40 nmol of synthetic peptide was applied (flow rate = 250 
JLl/min). Ten column volumes (20 ml) of flow-through frac-
tion was collected. Ten column volumes of elution buffer (2 
M urea/0.2 M ammonium acetate, pH 6.8/2 mM EDTA) was 
then applied to the column and the column effluent was col-
lected. To quantitate the peptide in each fraction, aliquots 
were analyzed by reversed-phase HPLC (Vydac C-4 analyti-
cal column) using a linear gradient from 0.1% trifluoroacetic 
acid to 0.1% trifluoroacetic acid/50% acetonitrile. The pep-
tide was detected by UV absorbance (206 nm) and trypto-
phan fluorescence (excitation, 280 nm; emission, >300 nm), 
identified by its elution time, and quantitated by absorbance 
peak height. Only 1% of the applied peptide was present in 
the calmodulin-Sepharose flow-through fraction, but 86% of 
the peptide was recovered upon elution with EDT A. Thus, 
the peptide interacts with calmodulin in a Ca2+ -dependent 
manner even in the presence of 2 M urea. When these ex-
periments were performed in the absence of urea, only a 
small percentage of applied peptide (3%) eluted with 2 mM 
EDT A, indicating that a denaturant is required for quantita-
tive dissociation from calmodulin-Sepharose. Since denatur-
ing conditions are not required for elution of intact MLCK 
from calmodulin-Sepharose, these experiments indicate dif-
ferences in the way that the peptide and the whole protein 
interact with calmodulin. 
DISCUSSION 
Although calmodulin is known to regulate a large number of 
enzyme activities, little is known about the interactions be-
tween calmodulin and its target enzymes at the molecular 
level. One reason is the lack of information regarding the 
amino acid sequences of calmodulin-dependent enzymes. 
One of our primary objectives in undertaking the sequence 
determination of MLCK was to identify the sequence of its 
calmodulin-binding domain. We report here evidence to indi-
cate that we have isolated a calmodulin-binding fragment 
from MLCK that displays the properties expected of a bona 
fide calmodulin-binding domain. 
A number of criteria should be satisfied by a peptide frag-
ment that is thought to act as the calmodulin-binding domain 
of a calmodulin-dependent enzyme. The peptide M13 isolat-
ed from MLCK fulfills the following criteria: (i) it is present 
in forms of the enzyme known to be calmodulin-dependent 
but absent from a form that is calmodulin-independent; (ii) it 
has a binding affinity for calmodulin comparable to that of 
the intact enzyme; (iii) its stoichiometry of interaction with 
calmodulin is identical to that of the intact enzyme; (iv) its 
interaction with calmodulin is Ca2+ -dependent; (v) its inter-
action with calmodulin prevents calmodulin's interaction 
with the enzyme. This list of criteria is by no means com-
plete but rather represents a starting point for the further 
investigation of putative calmodulin-binding domains. 
The sequence of the calmodulin-binding fragment of 
MLCK (Fig. 3) and its position within the overall sequence 
of the enzyme have been determined (unpublished observa-
tions). The peptide is 27 amino acids in length and represents 
the carboxyl terminus of MLCK. The sequence shows no 
significant homology with any protein in the current protein 
sequence data base (>2900 entries), as indicated by the 
SEARCH program (24). There is no obvious homology be-
tween M13 and either the 'Y subunit of phosphorylase kinase 
(25) or the inhibitory subunit oftroponin (troponin-I; ref. 26), 
the only proteins in the data base known to bind calmodulin. 
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This lack of homology may reflect either convergent evolu-
tion of calmodulin-binding domains in these different pro-
teins or different modes of interaction between each protein 
and calmodulin. Although troponin-I has been used as a 
model calmodulin-binding protein because of its relatively 
high affinity for calmodulin (3 nM; ref. 27), it is thought to be 
associated with troponin-C rather than calmodulin in vivo. 
The interaction of calmodulin with the 'Y subunit of phos-
phorylase kinase is also different than with MLCK in that 
calmodulin is an integral subunit of native phosphorylase ki-
nase and is not readily dissociated from the enzyme in the 
absence of Ca2+ (28). The calmodulin-dependent enzymes 
that most resemble MLCK in their mode of interaction with 
calmodulin (e.g., cyclic nucleotide phosphodiesterase, cal-
cineurin, adenylate cyclase, plasma membrane Ca2+ -pump 
ATPase, etc.) may be more interesting to compare with M13 
as sequence data become available. 
The primary structure of the calmodulin-binding peptide 
(Fig. 3) has several interesting features that may relate to its 
calmodulin-binding function. It contains a high percentage of 
basic residues (30%) but has no acidic or prolyl residues. The 
basic residues are grouped in clusters with five near the ami-
no terminus of the peptide and three near the middle. These 
residues are very likely to be involved in the interaction of 
MLCK with calmodulin, since calmodulin is quite acidic and 
ionic interactions are known to be important in this interac-
tion (13). Between the two clusters of basic residues is a 
highly hydrophobic region (Fig. 3), which is also probably 
important in the interaction of MLCK and calmodulin since 
hydrophobic interactions are known to be involved in the 
interactions of calmodulin with MLCK and other target en-
zymes (13, 29, 30). The sequence also contains one trypto-
phanyl residue, located in the cluster of basic residues at the 
amino terminus. The fluorescence of this amino acid is in-
creased upon interaction with calmodulin (Fig. 4), suggesting 
that this particular tryptophan residue may have been in-
volved in the fluorescence changes observed by Johnson et 
al. (21) in their studies of MLCK-calmodulin interactions. 
Secondary structural predictions based on the technique of 
Chou and Fasman (15,16) indicate that the calmodulin-bind-
ing peptide of MLCK has a high probability of forming a 
helix over much of its length (Fig. 3). 
A number of peptides have been used as models for cal-
modulin-target enzyme interactions because of their high af-
finity for calmodulin (31-33). When the sequences of these 
peptides are compared to that of M13, there do not appear to 
be any striking similarities of sequence (Table 1). However, 
the model peptides and M13 all share three structural fea-
tures thought to be important for interactions with calmodu-
lin: clusters of basic residues; hydrophobic residues adjacent 
to the basic residues; predicted or observed a-helical struc-
ture (31-35). It will be important to compare these several 
peptides with respect to their three-dimensional structure 
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and with respect to their sites of interaction on calmodulin. 
It is worth noting that the peptide fragment from MLCK 
denoted M12 (Table 1) also has many of the primary struc-
tural features expected of a calmodulin-binding peptide but 
shows no detectable binding activity (Fig. 2). Moreover, it is 
present in both calmodulin-dependent and -independent 
forms of MLCK (unpublished observations). The carboxyl-
terminal sequence of M12 is compared to that of M13 and 
several model calmodulin-binding peptides in Table 1. The 
carboxyl terminus of M12 is basic, has a region of high hy-
drophobicity, and shows a high probability of forming a he-
lix. Moreover, the sequence of M12 is quite similar to that of 
vasoactive intestinal peptide, which is known to interact 
with calmodulin with reasonably high affinity (""'50 nM; ref. 
36). Thus, it is interesting that this peptide (MI2) does not 
bind to calmodulin with high affinity. Because M12 is locat-
ed at the carboxyl terminus of MLCK, just to the amino ter-
minus of M13, it may play some role in the regulation of 
MLCK by calmodulin; however, it does not appear to make 
significant contributions to the overall binding energy in the 
interaction of MLCK and calmodulin. 
That regions of MLCK other than those represented by 
M13 maly be important in MLCK-calmodulin interactions is 
suggested by the data from calmodulin-Sepharose chroma-
tography of synthetic M13. Whereas MLCK readily and 
quantitatively elutes from calmodulin-Sepharose under non-
denaturing cond.tions when free Ca2+ concentrations are re-
duced using chelat,Or, only a small fraction of synthetic M13 
elutes under these conditions (see Results). Both urea (2 M) 
and chelator are required to elute the peptide, suggesting 
that the sequence of M13 may lack determinants that are re-
quired for facile dissociation from calmodulin in the absence 
of Ca2+. Comparison of peptide-calmodulin versus MLCK-
calmodulin interactions will be important to determine the 
nature of these determinants. 
The demonstration that limited proteolytic digestion of 
MLCK yields a catalytically active, calmodulin-insensitive 
fragment (C35) that is lacking a calmodulin-binding domain 
(Fig. 1) indicates that MLCK is a protein kinase of chimeric 
character (37), consisting of at least two domains (i.e., cata-
lytic and regulatory). This idea is supported by comparison 
of the sequence ofMLCK to other protein kinase sequences. 
MLCK is clearly homologous with every other member of 
the protein kinase family in the region of the molecule identi-
fied as the catalytic domain (unpublished observations). 
However, evidence is lacking for homology in the region of 
the calmodulin-binding domain, even in the case of the 'Y 
subunit of phosphorylase kinase, which is known to bind cal-
modulin (38). Since many calmodulin-dependent enzymes 
can be modified by proteolytic cleavage to yield calmodulin-
independent forms (reviewed in ref. 1), it is likely that many 
calmodulin-dependent enzymes are chimeras with catalytic 
domains linked to calmodulin-binding domains. 
Table 1. Sequence comparison of the calmodulin-binding peptide derived from MLCK (M13) with another peptide 

















The peptide sequences labeled M13 and M12 are derived from rabbit skeletal muscle MLCK. The sequence shown for M12 
is only that of the carboxyl-terminal 26 residues (total peptide length is 36 residues). The following one-letter codes are used 
to designate each amino acid: A (alanine), R (arginine), N (asparagine), D (aspartic acid), C (cysteine), Q (glutamine), E 
(glutamic acid), G (glycine), H (histidine), I (isoleucine), L (leucine), K (lysine), M (methionine), F (phenylalanine), P 
(proline), S (serine), T (threonine), W (tryptophan), Y (tyrosine), V (valine). Basic residues are underlined. 
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In summary, we have isolated and sequenced a peptide 
from MLCK that appears to represent the calmodulin-bind-
ing domain of this enzyme. A synthetic version of the pep-
tide has been prepared to facilitate studies of the interaction 
of the peptide with calmodulin. The results presented here 
indicate that the peptide should prove useful in probing the 
interactions of calmodulin with its target enzymes. It is likely 
that other calmodulin-dependent enzymes will yield similar 
calmodulin-binding peptides, which will be interesting to 
compare from an evolutionary as well as a structural stand-
point. 
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